The Extremities Market was on track to post a strong Q120 finish but due to COVID-19 the market pulled up short
The Extremities Market was in position to post a strong finish in Q120, driven by gains in the US. But the market pulled up short due to the postponement of elective and non-urgent procedures resulting in the US Extremities Market, declining -1.9%, according to SmartTRAK Financial Dashboard.
Among the many topics covered in the comprehensive Q120 Extremities Market Recap* are:
We are pleased to announce that Joe Mish has joined the team at SmartTRAK as Director of Sales. Joe has 10+ years experience in medical device sales, with concentration on Joint Replacement and Spine & Robotic Technologies. Prior to joining SmartTRAK, Joe sold and implemented analytic software to manage value-based care and bundled payment, working with Stryker, LDR/ZimmerBiomet and Stryker Performance Solutions.
Meet Joe Mish:
What is your role with SmartTRAK? I will be joining the commercial team as Director of Sales.
What do you like about SmartTRAK? I’ll give you two perspectives here. First, with regards to the technology, I love the value proposition to our current and prospective customers. With the world being so volatile and business being severely disrupted (especially for surgery and device companies) being able to offer a solution to reduce risk, improve profitability and productivity makes this a fantastic time to partner with organization’s and build strong, long-lasting relationships. This was truly a deciding factor in making a career/company change. Second, with regards to the company, I love the people. Coming from multiple large Fortune 500 companies with very specific cultures, individuals and team comradery is often and easily overlooked. I have been so impressed with the professionalism, transparency and family vibe from every person I have engaged with and I have only been on board for a week! This feels like a very special group of incredibly talented people and I am honored to be a part of it.
A study of 1,806 nurses from 10 hospitals in China on nurses' knowledge, attitudes and behaviors for promoting PI-prevention found 41.7% had insufficient PI-prevention knowledge, 46.6% had negative PI-prevention attitudes, and 21.8% had poor PI-prevention behavior. J Clin Nurs
Establishment Labs’ US Patent Application “TEXTURED SURFACES FOR BREAST IMPLANTS” was published, describing irregularly-textured breast implants with significantly improved cellular response over current textured implants. 20200170771
Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm
According to SmartTRAK Financial Dashboard, Q120 revenue for the US Joint Fluid Replacement market was down -2.8%, which is within the range predicted by market leaders and physicians in SmartTRAK’s Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA*. Albeit revenue is down for Q120, the stay-at-home orders across US states triggered by the rapid spread of COVID-19 were not implemented until mid-March, which helped to mitigate what could have been much bigger losses.Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:
COVID-19 pandemic hit the brakes mid-March resulting in a quick growth slow-down
Q120 was looking like a strong first quarter following Q420’s 4.5% YoY growth, the highest rate seen in the US Total Joints Market for several years. But, the COVID-19 pandemic and the institution of stay-at-home orders in most US states put the brakes on elective procedures in March, resulting in -4.8%, according to SmartTRAK Financial Dashboard. The postponement of procedures and the resulting downturn in revenue late in Q120 also resulted in orthopedic companies withdrawing guidance due to uncertainty about the timing of recovery.
Among the many topics covered in the comprehensive Q120 US Total Joints Market Recap* are:
As access to healthcare continues to open up, the orthopedic industry is taking significant precautions to insure the health, safety and piece of mind of patients and caregivers and balance that with its attempt to ramp up services and procedures. The following is a small sampling of the orthopedic updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:
Updated Survey Data Points to Recovery by Q420WFS’ new survey of 623 US-based physicians (15 specialties) shows that in orthopedic, the % of procedures expected to be postponed due to COVID-19 for both TKR and THR declined from 94% (Wave 1) to 85% (Wave 2). WFS MedTec: Updated Survey Data Points to Recovery by Q420
Of deferred spinal fusion procedures, surveyed surgeons now expect 74% of cases to be performed at a later date w/ 26% cancelling. Reasons for cancellation include pt seeking treatment w/ a different surgeon (26%) and underlying condition improving (23%). WFS MedTech Survey
Based on its survey of 623 US-based physicians across 15 specialties between April 27 and May 8, WFS notes that in general the % of robotic & laparoscopic procedures across all specialties declined compared to pre-COVID 19 levels, while the % of open procedures increased.
.SmartTRAK discusses a new biomaterials opportunity for medical devices with Michael Ziebell, President and CEO of trū Shrimp.
Shrimp is the most popular seafood in the US with an annual consumption of 1.6 billion pounds and 90% sourced outside the US. trū Shimp has developed a unique aquaculture for raising shrimp that allows production to occur anywhere in the US, even in Minnesota. Michael Ziebell explains the unique features of the process and its ability to produce a novel biomaterial that may be tailored to meet the needs of the medical device industry.
A transcript of SmartTRAK’s interview with Michael Ziebell is below. To listen to the audio interview, click on the video (10:39 minutes). The full transcript, with a link to download a PDF, is provided below.
With social distancing and travel restrictions easing worldwide, and WHO warning of a possible second peak of the pandemic, the work continues on potential vaccines to prevent COVID-19 and treatments for those already affected by the virus. The following is a small sampling of the COVID-19 updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:
Preliminary results of a double-blind, randomized, placebo-controlled trial of IV remdesivier in adults hospitalized w/ COVID-19 and lower respiratory tract infection showed remdesivir was superior to placebo in shortening recovery times (11 days vs 15 days; p=0.001). NEJM
This JBJS article discusses medically necessary orthopaedic surgery during the COVID-19 pandemic and recommends safe surgical practices and a classification to guide tx. JBJS
The US plans a massive testing effort involving more than 100K volunteers and ~6 of the most promising vaccine candidates in an effort to deliver a safe and effective one by YE20, compressing what is typically 10 yrs of vaccine development/testing into a matter of months. Reuters
Moderna reports preliminary data suggests its COVID-19 vaccine is safe and appears to be eliciting an immune response in test subjects. The FDA has given the Company approval to begin a Phase II study w/ ~600 volunteers. A Phase III study may begin by July. NPR
SmartTRAK discusses the latest advancements in biomedical solutions with DSM President John Witkowski
DSM, a global leader in biomedical solutions for more than 30 years, helps improve the health of 3.5 million patients annually. While biomaterials have been around for decades, DSM Biomedical is advancing biomaterial science, providing the latest synthetic biomaterials and stem cell-based technologies that are used in various applications, including spine, general orthopedics, sports medicine, general surgery and wound.
To learn more about the latest advancements in DSM Biomedical biomaterials and technologies and what’s next for the business, click on the following video to listen to SmartTRAK’s interview with John Witkowski, President of DSM Biomedical. A transcript of the interview can also be downloaded below.
We are excited to announce the launch of Computer Assisted Surgery's Financial Dashboard. SmartTRAK's financial analysis is highly regarded and frequently cited by many in the industry for its accuracy and comprehensiveness. As the Computer Assisted Surgery industry continues to evolve, it's more important than ever for industry players to stay on top of the market financials.
Financial Dashboard makes it easy to:
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.